Biomarker for diagnosis of gastric cancer
AssigneeSamsung Life Public Welfare Foundation
InventorsJee Yun LEE, Min Ae AN
Life of this patent
Estimating the term…
Abstract
Proposed are a biomarker for diagnosis of advanced gastric cancer and a use thereof. Specifically, by measuring the level of epithelial cells in which serine peptidase inhibitor, Kunitz type 2 (SPINT2), or post-glycosylphosphatidylinositol (GPI) attachment to proteins 3 (PGAP3) is highly expressed, from a biological sample of a patient, the efficiency in diagnosis of gastric cancer was confirmed to be excellent. Thus, the level of the biomarker can be measured and utilized for prevention, improvement, and/or treatment of gastric cancer.
Claims9
A method of providing information on diagnosis of gastric cancer, the method comprising:
- measuring a level of epithelial cells in which factor of SPINT2 or PGAP3 is highly expressed, from a biological sample isolated from an individual.
A method of screening a drug for treatment of gastric cancer, the method comprising:
- measuring a level of epithelial cells in which factor of SPINT2 or PGAP3 is highly expressed, from a biological sample isolated;
- bringing a test substance in contact with the biological sample;
- measuring a level of the epithelial cells, in which factor is highly expressed, from the biological sample after making contact with the test substance;
- and
- determining the test substance as a drug for treatment of gastric cancer when the level of the epithelial cells, in which factor is highly expressed, decreases within the biological sample.
Dependencies are inferred from the claim text.